Gender-specific differences in major cardiac events and mortality in lamin A/C mutation carriers.

  • Ingrid A.W. van Rijsingen*
  • , Eline A. Nannenberg
  • , Eloisa Arbustini
  • , Perry M. Elliott
  • , Jens Mogensen
  • , Johanna F. Hermans-van Ast
  • , Anneke J. van der Kooi
  • , J. Peter van Tintelen
  • , Maarten P. van den Berg
  • , Maurizia Grasso
  • , Alessandra Serio
  • , Sharon Jenkins
  • , Camilla Rowland
  • , Pascale Richard
  • , Arthur A.M. Wilde
  • , Andreas Perrot
  • , Sabine Pankuweit
  • , Aeilko H. Zwinderman
  • , Philippe Charron
  • , Imke Christiaans
  • Yigal M. Pinto
*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

53 Citations (Scopus)

Abstract

Mutations in the lamin A/C gene (LMNA) cause a variety of clinical phenotypes, including dilated cardiomyopathy. LMNA is one of the most prevalent mutated genes in dilated cardiomyopathy, and is associated with a high risk of arrhythmias, sudden cardiac death, and heart failure. There are few data on the impact of age and gender on cardiac disease penetrance and mortality. In a multicentre cohort of 269 LMNA mutation carriers, we evaluated gender-specific penetrance of cardiac involvement and major cardiac events. All-cause mortality of mutation carriers [standardized mortality ratio (SMR)] was determined. Cardiac disease penetrance was age dependent and almost complete at the age of 70 years. The presence of an LVEF ≤45% was significantly higher in men (P < 0.001). However, there was no difference between genders in the prevalence of atrioventricular block, atrial tachyarrhythmias, and non-sustained ventricular tachycardia. Malignant ventricular arrhythmias (26% vs. 8%) and end-stage heart failure (28% vs. 14%) were more common in men than in women (P < 0.001 and P = 0.006, respectively). All-cause mortality of mutation carriers was significantly increased [SMR 4.0, 95% confidence interval (CI) 2.8-5.2] between the ages of 15 and 75 years. Mortality in men was higher than in women (hazard ratio 2.2, 95% CI 1.2-4.3). This large cohort of LMNA mutation carriers demonstrates a high cardiac disease penetrance and a high mortality in mutation carriers. Male mutation carriers have a worse prognosis due to a higher prevalence of malignant ventricular arrhythmias and end-stage heart failure.

Original languageEnglish
Pages (from-to)376-384
Number of pages9
JournalEuropean Journal of Heart Failure
Volume15
Issue number4
DOIs
Publication statusPublished - 1 Apr 2013
Externally publishedYes

Fingerprint

Dive into the research topics of 'Gender-specific differences in major cardiac events and mortality in lamin A/C mutation carriers.'. Together they form a unique fingerprint.

Cite this